Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: A cardiac MR imaging study

Radiology

Volumn 277, Issue 2, 2015, Pages 388-397

  Fontana, Marianna ^a,b   Banypersad, Sanjay M ^a,b   Treibel, Thomas A ^a,b   Abdel Gadir, Amna ^a,b   Maestrini, Viviana ^a,c   Lane, Thirusha ^b   Gilbertson, Janet A ^b   Hutt, David F ^b   Lachmann, Helen J ^b   Whelan, Carol J ^b   Wechalekar, Ashutosh D ^b   Herrey, Anna S ^a   Gillmore, Julian D ^b   Hawkins, Philip N ^b   Moon, James C ^a,b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMYLOID; IMMUNOGLOBULIN LIGHT CHAIN; PREALBUMIN; TROPONIN T; BIOLOGICAL MARKER; CONTRAST MEDIUM; GADOTERATE MEGLUMINE; MEGLUMINE; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ARTICLE; CARDIAC IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS; CARDIAC TRANSTHYRETIN AMYLOIDOSIS; CARDIOVASCULAR MAGNETIC RESONANCE; CELL SIZE; CELL VOLUME; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EXTRACELLULAR SPACE; FEMALE; HEART AMYLOIDOSIS; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE MASS; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; VERY ELDERLY; WILD TYPE; AMYLOIDOSIS; CARDIOMYOPATHY; CASE CONTROL STUDY; FAMILIAL AMYLOID POLYNEUROPATHY; MIDDLE AGED; MUSCLE CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; AMYLOID NEUROPATHIES, FAMILIAL; AMYLOIDOSIS; BIOMARKERS; CARDIOMYOPATHIES; CASE-CONTROL STUDIES; CONTRAST MEDIA; ECHOCARDIOGRAPHY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; MUSCLE CELLS; ORGANOMETALLIC COMPOUNDS; PROSPECTIVE STUDIES;

EID: 84946014860     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2015141744     Document Type: Article

References (25)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349(6):583-596.
2. Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc 2012;1(2):e000364.
3. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 2005;165(12):1425-1429.
4. Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 1997;78(1):74-82.
5. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease pro-fles and clinical courses of the 3 main types. Circulation 2009;120(13):1203-1212.
6. Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Car-diovasc Imaging 2010;3(2):155-164.
7. Perugini E, Rapezzi C, Piva T, et al. Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 2006;92(3):343-349.
8. Pinney JH, Whelan CJ, Petrie A, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc 2013;2(2):e000098.
9. Dungu JN, Valencia O, Pinney JH, et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging 2014;7(2):133-142.
10. Suhr OB, Anan I, Backman C, et al. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin am-yloidosis? J Intern Med 2008;263(3):294-301.
11. Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004;94(8):1008-1010.
12. Karamitsos TD, Piechnik SK, Banypersad SM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Car-diovasc Imaging 2013;6(4):488-497.
13. Fontana M, Banypersad SM, Treibel TA, et al. Native T1 mapping in transthyre-tin amyloidosis. JACC Cardiovasc Imaging 2014; 7(2): 157-165.
14. Bull S, White SK, Piechnik SK, et al. Human non-contrast T1 values and correlation with histology in diffuse fbrosis. Heart 2013;99(13):932-937.
15. Ferreira VM, Piechnik SK, Dall'Armellina E, et al. T(1) mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-weighted and late gadolinium enhanced imaging. JACC Cardiovasc Imaging 2013;6(10):1048-1058.
16. Banypersad SM, Sado DM, Flett AS, et al. Quantifcation of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 2013;6(1):34-39.
17. Flett AS, Hayward MP, Ashworth MT, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fbrosis: preliminary validation in humans. Circulation 2010;122(2): 138-144.
18. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain am-yloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79(4):319-328.
19. Perugini E, Guidalotti PL, Salvi F, et al. Non-invasive etiologic diagnosis of cardiac amy-loidosis using 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46(6):1076-1084.
20. Fontana M, White SK, Banypersad SM, et al. Comparison of T1 mapping techniques for ECV quantifcation: histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantifcation equilibrium contrast CMR. J Cardiovasc Magn Reson 2012; 14: 88.
21. Piechnik SK, Ferreira VM, Dall'Armellina E, et al. Shortened modifed Look-Locker inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardio-vasc Magn Reson 2010;12:69.
22. Moon JC, Messroghli DR, Kellman P, et al. Myocardial T1 mapping and extracellular volume quantifcation: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson 2013;15(1):92.
23. Ferreira VM, Piechnik SK, Dall'Armellina E, et al. Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance. J Car-diovasc Magn Reson 2012;14:42.
24. Quarta CC, Solomon SD, Uraizee I, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation 2014;129(18):1840-1849.
25. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122(1):78-84.